Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Pieris AG, a Aagami client, Signs Alliance for Novel Anticalin® Therapeutics with Zydus of India--cMet antagonist, PRS-110, to be the flagship program-- 16 October 2013: Freising, Germany; Naperville, USA
By: Aagami, Inc Aagami, Inc. a Naperville IL based Strategic and Global Advisory firm supported Pieris in this deal. Pieris CEO, Stephen Yoder, said, “With state-of-the- For further information on the deal, please click on http://www.pieris- About Aagami: Aagami Inc.a Strategic Consulting Firm focused on bringing success to Global Pharma, Biotech and Medical Devices companies in their initiatives for India, Asia and other emerging markets. Aagami Partners bring several decades of operational experience globally, connections at C-Level people with Indian Life-sciences companies and most importantly deep knowledge of India/Asia-business- About Pieris & Anticalins Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalins promise to address high-unmet medical needs and expand the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has, in addition to Zydus, ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier biotechnology- Anticalins® are recombinantly engineered versions of human lipocalins, low-molecular weight polypeptides that naturally bind, store and transport a wide spectrum of molecules. To make Anticalins, Pieris makes discrete changes to those lipocalin amino acid positions responsible in endogenous ligand binding, thereby redirecting specificity away from the natural ligand and to virtually any target of interest. By utilizing an endogenous binding protein as a template, Pieris “hijacks” the natural function of the lipocalin to enable diverse therapeutic applications. --END-- Anticalin®, Anticalins® are registered trademarks of Pieris AG End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|